ArticleClinical and experimental immunology2005
Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.
Article in Clinical and experimental immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 96 citations in OpenAlex.
- Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.PloS one · 2012Trial
- Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.Lancet (London, England) · 2010Trial
- Mechanistic Insights, Treatment Paradigms, and Clinical Progress in Neurological Disorders: Current and Future Prospects.International journal of molecular sciences · 2023Review
- In Silico Drug Repurposing in Multiple Sclerosis Using scRNA-Seq Data.International journal of molecular sciences · 2023Article
- Adoptive T-cell therapy targeting Epstein-Barr virus as a treatment for multiple sclerosis.Clinical & translational immunology · 2023Review
- Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.Frontiers in immunology · 2021Review
- The role of B cells in the immunopathogenesis of multiple sclerosis.Immunology · 2020Review
- Immunological Aspects of Approved MS Therapeutics.Frontiers in immunology · 2019Review
- Reassessing B cell contributions in multiple sclerosis.Nature immunology · 2018Review
- Neurobehavioral burden of multiple sclerosis with nanotheranostics.Neuropsychiatric disease and treatment · 2015Review
- Review
- Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes.International journal of molecular sciences · 2013Article
- A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.Journal of neurology · 2012Review
- Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Clinical Medicine Insights. Oncology · 2012Article
- Neurological disorders and therapeutics targeted to surmount the blood-brain barrier.International journal of nanomedicine · 2012Review
- Managing MS in a changing treatment landscape.Journal of neurology · 2011Review
- Review
- Chemotherapeutics in the treatment of multiple sclerosis.Therapeutic advances in neurological disorders · 2010Article
- Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells.Molecular and cellular biochemistry · 2010Article
- B cells as a target of immune modulation.Annals of Indian Academy of Neurology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitoxantrone (MX) is a cytotoxic drug with proven clinical efficacy in active multiple sclerosis (MS). In this ex vivo study we investigated the immunological effects of MX on peripheral blood leucocytes (PBL) from MS patients. PBL were isolated from 46 patients with active MS (mean age 42 years, female : male 1.4 : 1) before and immediately after 1 h MX infusion. Isolated PBL were cultured and stimulated with phytohaemagglutinin (PHA), T cell receptor stimulating monoclonal antibody (MoAb) X35 or kept in culture medium alone. Proliferation was measured by [3H]-thymidine incorporation. MX-uptake and cell death in PBL subpopulations was analysed by flow cytometry using antibodies against cluster of differentiation (CD)-surface antigens, annexin V (AnnV) and propidium iodide (PI). MX was incorporated rapidly into PBL. After only a 1-h in vivo exposure, MX reduced proliferative responses in unstimulated and stimulated PBL (PHA: - 17%, MoAb X35: -13%). MX-exposed PBL showed an increase of AnnV+/PI+ cells (unstimulated: 12%, PHA: 15%), which was even more pronounced 2 weeks after infusion. No difference was observed between de novo MX-treated patients and those on long-term MX treatment. In T cell receptor stimulated PBL, cell death was induced preferentially in CD19-positive B cells and to a lesser extent in CD8-positive T cells. MX is incorporated rapidly in circulating PBL of MS patients and induces a pronounced suppression of proliferative responses. This suppression appears to be mediated at least partly by the induction of late apoptotic/necrotic cell death with a preferential susceptibility of B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.